Phillips B A, Zilko P, Garlepp M J, Mastaglia F L
Australian Neuromuscular Research Institute, University Department of Medicine, Queen Elizabeth II Medical Center, Nedlands.
Muscle Nerve. 1998 Dec;21(12):1668-72. doi: 10.1002/(sici)1097-4598(199812)21:12<1668::aid-mus7>3.0.co;2-#.
The frequency of clinical and biochemical relapses was determined in a group of 50 patients with polymyositis (PM), dermatomyositis (DM), or overlap syndromes who were followed for periods of up to 13 years. Relapses occurred in 30 of the 50 patients (60%) during the period of follow-up. The annual relapse rate was not significantly different in the three groups of patients. Subclinical relapses occurred in each group but were less frequent in the DM than in the PM and overlap groups. Relapses could occur at any time but were more frequent during periods of stable maintenance therapy. There was no correlation between relapses and initial disease severity, delay to diagnosis and commencement of treatment, or any class I or II histocompatibility locus antigen.
在一组50例患有多发性肌炎(PM)、皮肌炎(DM)或重叠综合征的患者中确定了临床和生化复发的频率,这些患者的随访时间长达13年。在随访期间,50例患者中有30例(60%)出现复发。三组患者的年复发率无显著差异。每组均发生亚临床复发,但DM组的亚临床复发频率低于PM组和重叠综合征组。复发可在任何时间发生,但在稳定维持治疗期间更为频繁。复发与初始疾病严重程度、诊断延迟和开始治疗时间,或任何I类或II类组织相容性位点抗原之间均无相关性。